Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study

Bone Marrow Transplantation

Volumn 23, Issue 2, 1999, Pages 163-168

  Kelsey, S M ^a   Goldman, J M ^b   McCann, S ^c   Newland, A C ^a   Scarffe, J H ^d   Oppenheim, B A ^d   Mufti, G J ^e  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

AmBisome; Neutropenia; Prophylaxis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; ASPERGILLUS; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANDIDA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEVER; HEADACHE; HUMAN; HYPOKALEMIA; HYPONATREMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; VOMITING;

EID: 0032913885     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701543     Document Type: Article

References (30)

1. Jehu V. Managing fungal and viral infection in the immunocompromised host. Rec Res Cancer Res 1988; 108: 61-70.
2. Goodrich JM, Reed EC, Mori LD et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-740.
3. Guiot HFL, Fibber WE, van't Wout JK. Risk factors for fungal infections in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18: 525-532.
4. Morrison VA, Haake RJ, Weisdorf DJ. Nan-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994; 96: 497-503.
5. Mossad SB, Longworth DL, Goormastic M et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265-271.
6. Jones PG, Kauffman CA, McAuliffe LS et al. Efficacy of ketoconazole vs nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med 1984; 144: 549-551.
7. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment vs placebo or no treatment in patients with cancer complicated by neutropenia. Br Med J 1997; 314: 1238-1244.
8. Heinemann V, Schwartz S, Behre G, Beyer J. Aerosol amphotericin B for prevention of invasive Aspergillus infections in neutropenic patients - results of a prospective randomized trial. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997 (Abstr. LM87).
9. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 841-851.
10. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
11. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172: 1035-1041.
12. Lopez-Berenstein G, Bodey GP, Fainstein V et al. Treatment of hepatosplenic candidiasis with liposomal amphotericin B. J Clin Oncol 1987; 5: 310-317.
13. Lopez-Berenstein G, Bodey GP, Fainstein V et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Int Med 1989; 149: 2533-2536.
14. Sculier JP, Coune A, Meunier F et al. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Clin Oncol 1988; 24: 527-538.
15. Tollemar J, Ringdén O, Tyden G. Liposomal amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin Transplant 1990; 4: 167-175.
16. Ringdén O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28 (Suppl B): 73-82.
17. Meunier F, Prentice HG, Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28 (Suppl B): 83-91.
18. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal vs conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-718.
19. Walsh T, Bodensteiner D, Hiemenz J et al. A randomized double-blind trial of AmBisome (liposomal amphotericin B) vs amphotericin B in the empirical treatment of persistently febrile neutropenic patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997 (Abstr. LM90).
20. Tollemar J, Ringdén O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-582.
21. Tollemar JK, Hockerstedt B, Ericzon G et al. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 1995; 59: 45-50.
22. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978; 62: 1037-1040.
23. Verfaillie C, Weisdorf R, Haake R et al. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 177-184.
24. Milliken ST, Powles RL. Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis 1990; 12 (Suppl 3): S374-S379.
25. Morgenstern GR, Prentice AG, Prentice HG et al. Fluconazole vs itraconazole for antifungal prophylaxis in neutropenia. Poster presented at Trends in Invasive Fungal Infections, Barcelona, 5-8 November, 1997.
26. Sanford GR, Merz WG, Wingard JR et al. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980; 142: 503-509.
27. De Gregorio MW, Lee WMF, Ries CA. Candida infections in patients with acute leukaemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982; 50: 2780-2784.
28. Buchanan AG, Riben PD, Rayner N et al. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome. Clin Invest Med 1985; 8: 139-147.
29. Pittet D, Monod M, Suter PM et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-758.
30. Martino P, Girmenia C, Venditti M et al. Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer 1989; 64: 2020-2034.